Axordia collaborates with Lombard Medical Technologies PLC for the development of treatment of Coronary Artery Disease
Axordia Limited announced that it has signed a letter of intent to enter into a collaboration with Lombard Medical Technologies PLC (LMT) to co-develop a new generation of treatment for coronary artery disease - a regenerative stent. The collaboration between Lombard and Axordia is for a two and a half year project to develop a regenerative stent that encourages rather than restricts local vascular repair. Attaching Axordia's proprietary, stem cell-derived endovascular cells to Lombard Medical's PEP(TM) programmable polymer coating on the stent surface shall allow the human body to promote controlled vascular repair and heal the damaged coronary artery vessel wall.
The stent shall represent a major step forward into a new format for stent technology where early healing (endothelialisation) is promoted rather than using cytotoxic drugs on drug eluting stents (DES) which inhibit growth and can cause late stage thrombotic events. As a result this stent technology could revolutionise the DES market, according to Axordia.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
